everyone, call Welcome, call our the by operator. earnings Thanks, to am for Semb, first our I XXXX. joined Tara Chief Officer. quarter this of Financial on this morning
a me you with today's for quick Let call. provide agenda
quarter. our I'll as a the taken QX toward pandemic in response. that business I'll broader actions review discussion and as of the of have disruption result results as experienced then of have begin well that we the the turn impacted with COVID-XX factors the and a during our performance we
Following long-term initiatives we briefly this the disruption COVID-XX strategic longer-term as thoughts of part by our the pursuing growth our current due review updates our on business sharing discussion, and on and I'll are outlook. four conclude provide continued I strategy. to will
started representing the a performance of revenue an a Tara we operational the year. get We first-quarter our review With million, open questions. and detailed will XXXX quarter. year of financial during the you with XX% then financial over reported provide with $X let's that, before of our review results for first call decline total for
million as earnings XXXX. of on our end in came that our fourth we total XX, guidance provided Our at part revenue results million first range March $X of $X.X low of to report quarter the quarter
ranges driven execution a we against of Despite revenue corporate guidance the EBITDA results strong far reduce were CARES first, QX call. second, results guidance expenses results related that things: in were objectives end COVID part provisions income net tax by exceeded to the range, to low in GAAP of operating the provided benefit 'XX at our two earnings we and stated on Act. the tax These challenges; and our loss as light delivered related adjusted our of that changes
near-term first will will results in a as material flow later the profile item The And the XXXX. improve the benefit result our will OpEx provisions CARES adoption cash the coming reported refund initiatives of our quarters. in P&L Act our under tax in
geographic declines results to our of in a we experienced first and business From OUS Turning review both year-over-year revenue our quarter. standpoint, quarter. U.S. in the this
total U.S. declined sales year international million, Our sales year total XX% over declined year to $X.X million. while year $X.X over to X%
performance X% year XXXX, first-quarter each Energy $X to in OEM year generated to $X of in a line impacted In attributable year crisis. million. legacy lower were to The over of by terms revenue were period. COVID sales the the and orders our Rather, they business, in to of timing our million our year sales OEM largely business segments, not sales our our result in entirely prior the compared revenue business, XX% results in with expectations of compared declined were Advanced business declined to over OEM year
pandemic. reflects pieces by months the our while where revenue growth demand generators. impact The in of growth utilization QX with Energy technology generators Advanced growth XXXX Renuvion total pleased February. the in the impacted XX% of was business our XX% over COVID discussed year, in increased beginning based As by our Energy of performance quarter, the in year the markets growth trends We first the our the in our for in in first very the international two of the in driven strong in our spread COVID-related QX sales were initial hand call, of caused hand two XX% of over Advanced by and reflects revenue the pieces business, over disruption crisis growth sales months our
As QX begun signs trends as already mid-March to COVID. had result show our we see discussed on business call, of a disruption the of
had move the weeks we seen Specifically, as and our March. first in U.S. and a utilization, few in the slowdown first of adoption the markets then we international through
Instead, Given we our uncertainty for results time, QX. providing in provide XXXX only not was full at the that of expectations elected our level high financial year guidance to possible.
and to had We balance shared in quarter. we that business these the impact that of a COVID-XX the time factored information best the first from at our expectations QX significant on were based over
by candidly, Our performance COVID-XX was pandemic. a to business governments direct the and the deteriorated over range. modestly decline of sharper March we the in guidance call, had second earnings the following we our response actions of contemplated This protective taken experienced weeks half preventative than in our QX or sharply the was in result
reminder, of a using Helium majority As performed the Plasma elective. procedures are Technology overwhelming our
a to requiring And the procedures government temporarily. affected centers. be been close as elective result, to have In doctors' offices and postponed surgery substantially all outpatient U.S., of including performed customers procedures by and actions are facilities, Renuvion these many in nonessential businesses
across as U.S. cities these close begin the During March, businesses implemented restrictions. states to and temporarily
year the as XX% a across nearly rapid over sales and of year we experienced of closures trends in year the In nearly U.S. surgery distributors weeks two Energy our customers result. driven year. declining sales these by Advanced our of year U.S. a cosmetic international sales total declined timing year over over March, XX% XX% by over procedural declining of region, the last While deterioration varied March
U.S. in year specifically, than March over last declined deterioration Regarding weeks the sales of over more XX% the market two the year.
world. COVID-XX. the around the first to safety discussion Turning reacted protect a patients, our We to pandemic quickly during our been and employees, COVID-XX distributor closely. the monitoring has to response of quarter Apyx and health of Medical customers the partners
we manufacturing personnel shifts device our divided smaller environment, able multiple social distancing. allow operations. safe adequate for company, into medical a manufacturing manufacturing have ensure to continue we to the been As To
to all frequency employees protective protocols, We improvements have of on-site important our the while requiring wear also other cleanings. to facility increasing made equipment including and safety
restrictions have to all business and placed travel, until employees remotely the We further facilities restricted notice. employees that nonessential required also on access work
put do contact the addition in to the difficult to protect team we initiatives our implemented to customers our to sales with on their this sharpen customers this surgeon time. in engage safety, goal order to their training in with have everything mind, support ability our for provide In additional to sales have can place With direct we them during close virtually. reps existing focused health have remaining and in they we with
addition they also with target when prospective virtual and be continue In reach methods, occurs so that existing to recovery via the engaging and to cosmetic positioned return well accounts will customers surgeons procedures. to our elective out reps conducting to
helping are monitoring countries. challenges result partners our in of they their are navigate slower and them we closely face U.S., activities they as a respective seeing distributor the the Outside the of the demand
taken Lastly, light the in we important spending reduce steps our to have of crisis. COVID-XX
spending with during COVID-XX hiring began March, implementing XXXX and first we our in on to cost our reducing impact business response our restrictions. normal condition, the activities, of reflected While of beginning curtailing financial months travel the in business the expenses two
other until becomes the plan more of delayed business our capital identified We certain. have maximize expense be environment in that to outlook can areas order
on shows, to and professional and reductions as further include our discretionary spending, such trade marketing events spending These fees.
temporarily have activities clinical studies environment the in and able certain delayed to research R&D these we we and investment Additionally, efficiently. until projects are normalizes, pursue
period of the eliminated XXXX we procedure during achievement this accrual our bonus the the operating to environment. to objectives in have related Lastly, broader unprecedented the of uncertainty further reduce expense profile elective performance
continue the to market are so that business recovers our positioned as we our invest of future from areas this Importantly, growth, well in key we support pandemic.
have employees or changing any our intention we size the no notably, sales of at Most our this furloughing of of team time.
team, as considerable focused effort building growth we are strong crisis world-class training the subsides. well our are a drive spent We and return sales they to that ensuring prepared to on have and
a to built despite our times. say leadership team also strong challenging recent mission to the I these And team remains have in that committed am We proud years.
In addition, studies you skin including our dermal most in clinical investment our the longer-term for that clinical temporarily continue important to in studies, support and delayed while U.S. IDE certain are growth, we we resurfacing pursuing we like surgery have take areas research market. are long-term minute operational I'd now to initiatives the for growth cosmetic position Medical a update our progress on Apyx with to laxity. to strategic respect four the in to
to The that enable market and specific clinical will targeted for us sell Renuvion procedures. to new first one pursue indications
make In XXXX, our of clinical the we progress U.S. in new two first continued studies. IDE in months patients two to enrolling
for specifically to Clinical across pursue we designed dermal of and laxity our part skin use implemented reminder, and indications U.S. these of a studies trial for clinical Renuvion, the new strategy As resurfacing activity the procedures. as long-term
been have been COVID-XX impacted a created studies due and paused in the two by as significantly result. has disruption to these enrollment
Our is disruption closely safe considered clinical mitigate studies do to of from position working the with both this it to and is investigators impacts enrollment the to resume help once team us so.
studies, to unable to currently will when are this we at resume plan While both continue we we estimate be time. with position to enrollment in
regulatory initiative. to use the technology, our which our progress, to portfolio our of second expand of also continued efforts our strategic we supporting clinical addition is evidence In Renuvion our
published manuscript I first the publication remain study to pleased this am U.S. and submitted in manuscript announce of additional first In completing completed a peer-reviewed Lasers for least resurfacing. XXXX, for we the clinical submitting results Medicine. in three manuscripts During focused we April and quarter, publication. a dermal clinical our the on in IDE was at journal, that on Surgery and discussing
With third for cosmetic and customers. our strategic practice physician respect initiative, support to surgery our enhancing
and first new programs two proceeded at and expected. industry physician and the trade shows plans our presence expand mentor host months conferences our XXXX, or of as programming to educational PMPs During
pandemic. planned however, COVID-XX events due to Our were March, for canceled
prospects programming, and very in clinical lieu of our with teams around have our person this in marketing active and field world. been and customers engaging In the sales
customers range We a of topics, including leading where technology. have leading to speaking virtually results featured wide hosted our we of on clinician a competitor Renuvion some comparing side-by-side events educational
how events assist webinars strategies pricing case prospects week, Renuvion, thoughts and have marketing and studies to for to practice illustrate education patients post-COVID. installment of with opening new their their have we to planned Last ROI. the leading on designed our clinician a and virtual customers and our first their adopted hosted of also Our customers series included selling
continuing We and training calls in of hosting with multiple Renuvion J-Plasma international technology. about engaging outside sessions customers with distributors and international current Renuvion U.S., interested are with our the learning education also including prospects on clinical multiple groups
strategic And lastly, with respect initiative, to capabilities manufacturing our improve and our fourth efficiencies.
response many the to we to focus pandemic, and of the we well positioned in first a I faced, area continued record the weather will incredibly supporting pleased years operation ongoing and to COVID-XX our an subsides. to to remains and of Ultimately, as come. employees crisis the have Medical lean during implement quarter, return our strong Despite XXXX in period a shown of as continue it is in that been work face growth to commitment work have maintaining organization progress the to with our This result challenges new Apyx During order initiatives. history drive have we and such our the and company's our our customers to this delivering of difficult
First, we are believe years. our fund We our resources cash capitalized. sheet, have with we of multiple over well adequate million balance for $XX operations to on very
to our are our chain near-term the experiencing recover continue of to a sheet targeted significant And to of poised not control our and are to in-house as enhanced we and Second, invest that to support to long-term manufacturing the growth COVID-XX progressing respect safety of supply in disruption ensures our business protocols. strength us under any we pandemic, and our balance health expenses our elements and and quickly result progress allow our with strategy. our drive third, strategies is
of Simply our on for uncertainties challenge COVID-XX community's Given impact to on our continued current ongoing recognize the stated, an associated and had Advanced trends. increased that to with has their provide and investment COVID-XX patients represent customers significant quarter the Energy the our business. elected color the has clarity pandemic, we for the activity desire have
and U.S. sales deteriorate. during the international trends month April Our of continued to
trends customers' on the customers when the of allowed sales month the procedures year-over-year ultimately, A March. lifted amount restrictions undergo are terms be the during of choose to uncertainty to elective will in to of saw our significant remains cosmetic once our patients when Relative will reopen. we practices
of surgeon by our the respective announcements the soon reopening cosmetic in the two are We their to customers as place activities lifting expect we mandates initial and encouraged over restrictions weeks. offices And the their begin shelter related process to past state allow. of as
Naturally, the of increase demand an we for volume pace of the timing hand would related trends the technology uncertain. predict generator the to of our point, timing pieces see expect and related and improvement in uptick procedure-related when at improvement Renuvion procedure procedure remains elective remains in sales in we this elective time. At the in which trends this in lag highly adoption the Again, to difficult and environments. behind
our COVID-XX in market not the altered that competitive we the attractive pandemic has are advantages Importantly, and long-term pursuing. the opportunities
its manner, continues unique transform the to to in market. our performed efficient heat modality how deliver represent incredibly procedures With ability energy are tissue controlled in a Helium the Technology to ability Plasma surgery with and cosmetic to
to achieve from feedback and our cosmetic positive the they surgeons products. able have Renuvion outcomes highlighting plastic strong been with receive to continue We
unique the billion an technology that be estimated over alone. U.S. market the in pursue leveraging surgery is We to opportunity are this cosmetic market on $X.X for addressable to focused
market With pursue commercial At we significant as And years. technology. I surgery the same going that our to surgery us continue registrations earlier four have results has in growth we strategy adoption two broad-based strong of by opportunities international discussed time, in the U.S. new the outside demonstrated these opportunities the drive long-term cosmetic initiatives forward. to with position are a will the over last markets facilitating strategic the pursuing cosmetic key
global turn serve bringing others, earnings to their surgery release reasons to morning. our discuss elevating we we market the COVID-XX and to solutions this these review benefit subsides, work surgeon shareholders. in customers, our call continue are for in over of results crisis comments For poised cosmetic the the the many and customers patients our now and the and as our to Tara? I'll our Tara press of made financial first-quarter transformative detail the
